Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma | Zendy

D. Graceffa | Zendy; Elisa Maiani | Zendy; Andrea Pace | Zendy; F. M. Solivetti | Zendy; Fulvia Elia | Zendy; C. De Mutiis | Zendy; Claudio Bonifati | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma

Author(s) -

D. Graceffa,

Elisa Maiani,

Andrea Pace,

F. M. Solivetti,

Fulvia Elia,

C. De Mutiis,

Claudio Bonifati

Publication year - 2012

Publication title -

case reports in rheumatology

Language(s) - English

Resource type - Journals

eISSN - 2090-6889

pISSN - 2090-6897

DOI - 10.1155/2012/208606

Subject(s) - bevacizumab , medicine , psoriatic arthritis , vascular endothelial growth factor , psoriasis , glioma , dermatology , monoclonal antibody , vegf receptors , arthritis , oncology , antibody , immunology , cancer research , chemotherapy

Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research